Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
KCNJ11 3767 THIAMYLAL CHEMBL440 inhibitor TdgClinicalTrial, TEND, DrugBank 14739809, 15852621, 10754636
KCNJ11 3767 MINOXIDIL CHEMBL802 activator GuideToPharmacologyInteractions, ChemblInteractions
KCNJ11 3767 NICORANDIL CHEMBL284906 activator GuideToPharmacologyInteractions
KCNJ11 3767 TOLBUTAMIDE CHEMBL782 inhibitor, blocker GuideToPharmacologyInteractions, ChemblInteractions
KCNJ11 3767 TOLAZAMIDE CHEMBL817 blocker ChemblInteractions
KCNJ11 3767 DIAZOXIDE CHEMBL181 inducer PharmGKB, ChemblInteractions, DrugBank 10518593, 10581306, 10604939, 12770942, 11808879
KCNJ11 3767 VERAPAMIL CHEMBL6966 inhibitor DrugBank 11752352, 17038430, 17409272
KCNJ11 3767 FLECAINIDE CHEMBL652 NCI 11429398
KCNJ11 3767 STREPTOZOTOCIN CHEMBL1651906 NCI 11798815
KCNJ11 3767 CHLORPROPAMIDE CHEMBL498 blocker ChemblInteractions
KCNJ11 3767 NATEGLINIDE CHEMBL783 blocker ChemblInteractions, TEND
KCNJ11 3767 MITIGLINIDE CHEMBL471498 TEND
KCNJ11 3767 GLIMEPIRIDE CHEMBL1481 inhibitor, blocker TdgClinicalTrial, ChemblInteractions, NCI, TEND, DrugBank 12703060, 12086984, 11325810
KCNJ11 3767 SARAKALIM CHEMBL2104449 ChemblInteractions
KCNJ11 3767 GLIPIZIDE CHEMBL1073 blocker ChemblInteractions
KCNJ11 3767 REPAGLINIDE CHEMBL1272 blocker PharmGKB, ChemblInteractions, TEND
KCNJ11 3767 LEVOSIMENDAN CHEMBL2051955 TdgClinicalTrial
KCNJ11 3767 TOLBUTAMIDE SODIUM, STERILE CHEMBL1200874 blocker ChemblInteractions
KCNJ11 3767 ACETOHEXAMIDE CHEMBL1589 blocker ChemblInteractions
KCNJ11 3767 NAMINIDIL CHEMBL2105160 ChemblInteractions
KCNJ11 3767 PINACIDIL HYDRATE CHEMBL1200338 ChemblInteractions
KCNJ11 3767 PHENTOLAMINE CHEMBL597 NCI 9326676
KCNJ11 3767 GLYBURIDE CHEMBL472 inhibitor, blocker TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 9593694
KCNJ11 3767 EPIGALOCATECHIN GALLATE CHEMBL297453 NCI 17656102

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
KCNJ11 rs587783672 T sulfonamides, urea derivatives efficacy not stated Patients with the missense mutation KCNJ11 c. 679 G/A (E227K) were able to successfully transfer from insulin injections to an oral sulfonylurea, with improved glycemic control. Allele T is associated with response to sulfonamides, urea derivatives in children as compared to allele C. 22471336 1450378806
KCNJ11 rs5219 T repaglinide efficacy yes Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC. 20054294 655385756
KCNJ11 rs5219 T sulfonamides, urea derivatives efficacy no Allele T is not associated with decreased response to sulfonamides, urea derivatives. 11318841 827641446
KCNJ11 rs5219 C glibenclamide dosage no Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T. 24442125 1184470130
KCNJ11 rs5215 C glibenclamide dosage no Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T. 24442125 1184470125
KCNJ11 rs5219 CT sulfonamides, urea derivatives efficacy yes The CT genotype was associated with increased response to sulfonylureas (a greater than or equal to 7% decrease in Hb1Ac levels at least 3 months after beginning treatment). Genotype CT is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotypes CC + TT. 29681852 1449310639
KCNJ11 rs5215 T sulfonamides, urea derivatives efficacy no Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C. 29681852 1449310666
KCNJ11 rs5219 TT gliclazide efficacy yes Patients with the TT genotype (referred to by its amino acids, "KK" in the paper) were significantly more likely to attain the standard fasting glucose level as compared to patients with the CC or CT genotypes. Significant after adjustment for age, gender and body mass index (BMI) at baseline. Patients received gliclazide for 16 weeks. Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT. 25115353 1185235790